pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Sol
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
Tolinapant, Tolinapant
Phase 2 · small molecule · Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy
Tolinapant, Tolinapant for Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code ASTX660-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Taiho Pharma Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy
- Status
- active
- Trials
- 1